Dr. Twelves on Negative Phase III Iniparib Announcements

Video

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom on Negative Phase III Iniparib Announcements

Related Videos
Núria Agustí Garcia, MD
Erin Frances Cobain, MD
Kian-Huat Lim, MD, PhD
Joaquim Bellmunt, MD, PhD
Stephen V. Liu, MD
Olalekan O. Oluwole, MBBS, MD, associate professor, medicine, hematology/oncology, Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Debu Tripathy, MD
Related Content
Erin Frances Cobain, MD, of the University of Michigan Rogel Cancer Center

Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management

May 2nd 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Erin Frances Cobain, MD

The Road Beyond Frontline CDK4/6 Inhibitors in HR+/HER2– Metastatic Breast Cancer Examines Combinations

April 30th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca

Trastuzumab Deruxtecan Improves PFS in Metastatic HR+/HER2-Low Breast Cancer After Endocrine Therapy

April 29th 2024
Article
Mafalda Oliveira, MD, PhD

CHMP Recommends Capivasertib/Fulvestrant for Pretreated ER+/HER2– Advanced Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

April 29th 2024
Article